

“Searching for a Needle in a Needle Stack”**Hector Stiftung funds ultrasensitive mass spectrometer at DKFZ**

Which structures of cancer-causing human papillomaviruses (HPV) are promising targets for developing a therapeutic vaccine? Which markers can be found in the blood of pancreatic cancer patients? Associate Professor (PD) Dr. Dr. Angelika Riemer and Dr. Christoph Rösli, junior research group leaders at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), are studying these questions. The Hector Foundation II has now made a generous donation to fund a special instrument for such studies, an ultrasensitive mass spectrometer. Founder Dr. h.c. Hans-Werner Hector himself visited DKFZ to take a look at the €500,000 instrument.

“As a junior scientist, it is not easy to finance an instrument for half a million euros through the usual external funding sources such as the German Research Foundation or the Federal Research Ministry,” says Christoph Rösli summing up the starting situation for him and his colleague, Angelika Riemer. For their research, they both need a mass spectrometer for detecting the smallest amounts of tiny protein molecules in a highly complex mixture – a needle in a needle stack. BioRN Cluster Management, an intermediary between various partners related to life sciences in the Rhine-Neckar region, opened the right door for them. “They made contact with the Hector Stiftung,” said Riemer. A telephone conversation with Hans-Werner Hector eventually brought the desired result.

Angelika Riemer develops a therapeutic HPV vaccine, which shall also help patients with an existing HPV infection. Currently available HPV vaccines are preventive, i.e. they protect against infection with the virus. However, they are ineffective once the virus has infected cells of the cervix, the anal area or the oral cavity. “We are looking for targets,” Riemer explains. “Infected cells present fragments of the virus they carry inside on their surface. The new mass spectrometer will enable us to identify those fragments.” Riemer plans to use these protein fragments for immunizing infected people, so their immune systems can recognize and eliminate virus-infected cells. Austrian-born Riemer, aged 36, already worked on therapeutic vaccines at Harvard Medical School in Boston, U.S.A.

Christoph Rösli, who heads a research group at the stem cell institute HI-STEM at DKFZ, focuses on pancreatic cancer. “Most recent findings indicate that there are at least three distinct patient groups which differ in the way they respond to therapy. Up to now, all patients have been given roughly the same treatment. If we knew which drugs work best for each group, we could make treatment a lot more effective,” he describes his research approach. Rösli and his team are studying malignant stem cells which they have isolated from pancreatic tumors and subsequently grown in cell culture. The scientists found the tumor stem cells from the different patient groups releasing different protein molecules to their environment to promote their own blood supply and tumor growth. Using the new mass spectrometer, Rösli aims to find out whether this also holds true for the situation in patients and whether these proteins are also released into the bloodstream. “We want to determine from a blood sample prior to treatment who will benefit most from which drugs,” says 33-year-old Rösli, who is from Switzerland and previously worked at ETH Zurich.

“We owe a big thank to Hans-Werner Hector and his foundation,” said Prof. Dr. Dr. h.c. Otmar Wiestler, Chairman of the Management Board and Scientific Director of DKFZ, on the occasion of Hector’s visit. “If we want to compete for the world’s best scientists from the internationally most renowned research institutes, we have to offer top working conditions.

This includes providing the most advanced high-tech instruments.” Hans-Werner Hector said: “Germany has no natural resources, our assets are smart brains. And we enjoy supporting them!”

Pictures for download are available at:

www.dkfz.de/de/presse/pressemitteilungen/2013/images/hector_01.jpg

Caption: Dr. h.c. Hans-Werner Hector, honorary senator and chairman of the board of the Hector Foundation II, PD Dr. Dr. Angelika Riemer, Dr. Christoph Rösli

www.dkfz.de/de/presse/pressemitteilungen/2013/images/hector_02.jpg

Caption: Uwe Bleich, member of the board of the Hector Foundation II, Prof. Dr. Peter Krammer, Dr. h.c. Hans-Werner Hector, honorary senator and chairman of the board of the Hector Foundation II, PD Dr. Dr. Angelika Riemer, Dr. Christoph Rösli, Prof. Dr. Dr. h.c. Otmar D. Wiestler, Horst-Bodo Schauer, member of the board of the Hector Foundation II

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Dr. Stefanie Seltmann
Leiterin Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de

Dr. Sibylle Kohlstädt
Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2843
F: +49 6221 42 2968
presse@dkfz.de